Table 1. Baseline characteristics.
| Variables | Values | ||
|---|---|---|---|
| Age (yr), median (range) | 56.5 (28–70) | ||
| BMI (kg/m2), median (range) | 21.0 (17.4–29.1) | ||
| Primary tumor location | |||
| Ovary | 25 (83.3) | ||
| Fallopian tube | 1 (3.3) | ||
| Peritoneum | 4 (13.3) | ||
| Histopathology | |||
| High-grade serous | 17 (56.7) | ||
| High-grade endometrioid | 1 (3.3) | ||
| Clear cell adenocarcinoma | 2 (6.7) | ||
| Carcinosarcoma | 2 (6.7) | ||
| Mucinous | 8 (26.7) | ||
| FIGO stage | |||
| Stage IIIC | 18 (60.0) | ||
| Stage IV | 12 (40.0) | ||
| Debulking surgery | |||
| PDS | 14 (46.7) | ||
| NACT/IDS | 16 (53.3) | ||
| Surgical procedures | |||
| Lymphadenectomy | 15 (50.0) | ||
| Small bowel resection | 1 (3.3) | ||
| Large bowel resection | 12 (40.0) | ||
| Hepatectomy | 1 (3.3) | ||
| Spleen resection | 1 (3.3) | ||
| Pancreas resection | 1 (3.3) | ||
| Diaphragmatic peritonectomy | 6 (20.0) | ||
| Surgical complexity score group | |||
| Low (score 1 to 3) | 15 (50.0) | ||
| Intermediate (score 4 to 7) | 12 (40.0) | ||
| High (score ≥8) | 3 (10.0) | ||
| Operation time (hr), median (range) | 4.5 (1.0–8.5) | ||
| Estimated blood loss (mL), median (range) | 175 (5–900) | ||
| Blood transfusion during surgery | |||
| Yes | 9 (30.0) | ||
| No | 21 (70.0) | ||
| Residual disease | |||
| 0 cm | 26 (86.7) | ||
| ≤1 cm | 4 (13.3) | ||
| ICU stay | |||
| Yes | 0 (0.0) | ||
| No | 30 (100.0) | ||
| Deleterious tumor BRCA mutation | |||
| Yes | 5 (16.7) | ||
| No | 17 (56.7) | ||
| Unknown | 8 (26.7) | ||
| Chemotherapy following debulking surgery | |||
| Three-week carboplatin/paclitaxel | 26 (86.7) | ||
| Carboplatin/liposomal doxorubicin | 1 (3.3) | ||
| Weekly carboplatin/paclitaxel | 1 (3.3) | ||
| Gastrointestinal-type chemotherapy | 2 (6.7) | ||
| Neoadjuvant chemotherapy* | |||
| Regimen | |||
| Three-week carboplatin/paclitaxel | 12 (75.0) | ||
| Weekly carboplatin/paclitaxel | 4 (25.0) | ||
| Neoadjuvant cycles | |||
| Two cycles | 2 (12.5) | ||
| Three cycles | 14 (87.5) | ||
| Frontline maintenance therapy | |||
| Bevacizumab | 11 (36.7) | ||
| Olaparib | 4 (13.3) | ||
| Bevacizumab + olaparib | 1 (3.3) | ||
| No | 14 (46.7) | ||
Values are presented as number (%) unless otherwise indicated.
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; ICU, intensive care unit; IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.
*16 patients received neoadjuvant chemotherapy.